AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01726920
Drug: naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets containing naproxen 500 mg
Trial: NCT01644617
Drug: MK-8237 12 DU
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-8237 12 DU rapidly dissolving tablets administered sublingually once daily
Trial: NCT00377832
Drug: Acetaminophen 975 mg
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 975 mg by mouth once only
Trial: NCT00958893
Drug: 25 mg Proellex
RxNorm normalized name: guaiacolsulfonate / hydrocodone bitartrate Oral Solution [Prolex DH]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one 25 mg capsules
Trial: NCT00475462
Drug: conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01907594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigators will administer Gelatin Capsule instead of D-Cycloserine in a double blind fashion to some of study subjects.
Trial: NCT00817518
Drug: RO4987655
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered po daily for 28 days, at escalating doses , with a starting dose of 1mg (Part 1). Optimal biological dose administered po daily until disease progression (Part 2)
Trial: NCT02539082
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, normal saline, injection in the defect area
Trial: NCT03930212
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: received placebo suppositories rectally once daily.
Trial: NCT00271401
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00271401
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02632708
Drug: AG-120
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04671316
Drug: DA-5209 60mg Tab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration of 1 tablet of DA-5209 60mg Tab with 150mL water
Trial: NCT04671316
Drug: DA-5209 60mg Tab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration of 1 tablet of DA-5209 60mg Tab without water
Trial: NCT00425763
Drug: AQAS
RxNorm normalized name: Acetylsalicylic acid
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AQAS dosed by body weight, on days 0, 1, 2
Trial: NCT02929888
Drug: Lysine Acetilsalicilate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01912378
Drug: Placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00369941
Drug: MK-0518
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg MK-0518 tablet taken by mouth (PO) twice a day (b.i.d.) for up to 240 weeks
Trial: NCT00369941
Drug: Comparator: Truvada
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet Truvada once a day (q.d.) for up to 240 weeks (one tablet contains 200 mg emtricitabine and 300 mg tenofovir)
Trial: NCT00980031
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25mg PO daily (QD)for 6 months
Trial: NCT00980031
Drug: Lactose Tablet
RxNorm normalized name: lactose Oral Tablet
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactose tablet
Trial: NCT01044264
Drug: 1% Clindamycin/5% Benzoyl Peroxide Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Gel
Trial: NCT01044264
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01724450
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo similar to the carvedilol up titration but wit no active drug.
Trial: NCT03437070
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered intravenously per protocol on Day 1 for 21-day cycles.
Trial: NCT02859142
Drug: NicodermCQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine patches provided over 12 week participation
Trial: NCT02859142
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical in appearance to varenicline \[0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then one 1.0 mg tablet twice per day\]
Trial: NCT02565511
Drug: CNP520
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CNP520 50 mg capsule p.o. for the duration of the Treatment Epoch.
Trial: NCT02057887
Drug: HM10660A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01230593
Drug: Hot Compress plus Tobramycin Drops and Ointment
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In addition to hot compress, Tobramycin drops will be given to the affected eye 3x/day, and Tobramycin ointment will be given at night before bed.
Trial: NCT01230593
Drug: Hot compress plus Tobramycin/Dexamethasone Drops and Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In addition to hot compress, Tobramycin/Dexamethasone drops will be given to the affected eye 3x/day, and Tobramycin/Dexamethasone ointment will be given at night before bed.
Trial: NCT03018626
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin(10 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
Trial: NCT03018626
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide(750 mg/m2)/dayg IV on days 5
Trial: NCT03018626
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (75 mg/m2) given intravenously (IV) on day 1,
Trial: NCT03018626
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (1,200 mg/m2) given intravenously (IV) on day 1,
Trial: NCT01449591
Drug: Noritate® 1% cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00746837
Drug: AZD5672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single IV doses starting at 7 mg, subsequent doses to be confirmed following review of PK and safety data after each treatment period
Trial: NCT00746837
Drug: AZD5672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg od, 12 days
Trial: NCT00746837
Drug: AZD5672
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg od, 12 days
Trial: NCT01227889
Drug: GSK2118436
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg twice daily
Trial: NCT01055743
Drug: Fluorouracil Implants
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Implanted during the surgical treatment
Trial: NCT00620308
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose 5% in water (the vehicle)
Trial: NCT05321524
Drug: OCA 0.1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily.
Trial: NCT05321524
Drug: OCA 1.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily.
Trial: NCT00135954
Drug: Cyclophosphamide and steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of difference in time of start of therapy
Trial: NCT03221582
Drug: EBR/GZR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elbasvir and Grazoprevir (EBR/GZR) tablet by mouth, once daily.
Trial: NCT01795222
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magistral formula prepared to match Dormire color and consistency, without active ingredients Placebo was administered the same way as midazolam
Trial: NCT02479412
Drug: 250 µg AZD7594 once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
Trial: NCT02479412
Drug: 58 µg AZD7594 once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
Trial: NCT02479412
Drug: Placebo once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily dosing of Placebo to AZD7594 for 14 days; each dose of Placebo inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
Trial: NCT02264067
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003011
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg PO BID
Trial: NCT00783536
Drug: DMARDS
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00532961
Drug: Loteprednol etabonate 0.5% and tobramycin 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ophthalmic suspension, four times daily during the day at roughly 4 hour intervals(1-2 drops per eye)for a total of 28 days
Trial: NCT00532961
Drug: Dexamethasone 0.1% and tobramycin 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ophthalmic suspension, four times daily during the day at roughly 4 hour intervals (1-2 drops/eye) for a total of 28 days.
Trial: NCT00953043
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medication given for three days
Trial: NCT03824925
Drug: Placebo oral Zinc capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Look alike cap of corn starch as a placebo of Zinc to be given on day 1 of chemo-radiotherapy
Trial: NCT03824925
Drug: Zinc Sulfate 220 MG
RxNorm normalized name: zinc sulfate 220 MG
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate in test group dose was 220 mg which is equivalent to 50 mg of elemental zinc
Trial: NCT00418834
Drug: Placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (unspecified) daily for 12 weeks
Trial: NCT02242227
Drug: Serevent® Diskus®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02242227
Drug: Placebo (HandiHaler®)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02242227
Drug: Placebo (Diskus®)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00352755
Drug: Intraperitoneal 5FU
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00352755
Drug: FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00478725
Drug: GW786034, oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, 800 mg
Trial: NCT00478725
Drug: GW786034, IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV, 5 mg
Trial: NCT00478725
Drug: GW786034, radiolabeled oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral, 400 mg radiolabeled
Trial: NCT01907984
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00734344
Drug: Emtricitibine
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg once daily
Trial: NCT03443960
Drug: TNX-102 SL 5.6 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects randomly assigned to this treatment will place 2 tablets simultaneously under the tongue until dissolved, and not to crush or chew them.
Trial: NCT03434119
Drug: Background therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Anti diabetics Drugs (OADs) administered orally according to the locally approved label.
Trial: NCT01184014
Drug: Complete Insulin Orders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-part insulin which includes background, meal-time and correction factor
Trial: NCT00745017
Drug: Antidepressant medication
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
Trial: NCT02528214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
Trial: NCT02528214
Drug: Oral corticosteroid therapy (prednisone/prednisolone)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration.
Trial: NCT02528214
Drug: Inhaled corticosteroid (ICS) therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral inhalation, stable dose (high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy).
Trial: NCT03862404
Drug: Bupivacaine-epinephrine
RxNorm normalized name: bupivacaine-epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See previous description
Trial: NCT03862404
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See previous descreption
Trial: NCT00102895
Drug: CP-724,714
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00489450
Drug: SK3530
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00153049
Drug: Telmisartan + Hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / telmisartan
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01490346
Drug: Initiation of anti-retroviral therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects begin taking a preferred initial anti-retroviral regimens as determined by their primary care provider. Intracellular levels of those medications are measured.
Trial: NCT01562574
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
Trial: NCT03799926
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo starting dose: 1 packet/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
Trial: NCT03799926
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo starting dose: 2 packets/day, orally, once daily. The dose of patiromer could be titrated based on subject's serum potassium response (stratum 1)
Trial: NCT01304836
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV \& oral
Trial: NCT01568047
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once-daily
Trial: NCT01568047
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 9-1067 - 5 mg single-dose
Trial: NCT01568047
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 9-1067 - 15 mg single-dose
Trial: NCT01568047
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 9-1067 - 30 mg single-dose
Trial: NCT01568047
Drug: Levodopa/Carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa 100 mg Carbidopa 25 mg
Trial: NCT01568047
Drug: Levodopa/Benzerazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa 100 mg Benzerazide 25 mg
Trial: NCT00817089
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill
Trial: NCT02277782
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02127801
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02962830
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intra-amniotic injection of 10 micrograms of Sufentanil
Trial: NCT00737841
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g of placebo, taking orally, 3 times a day for 8 weeks.
Trial: NCT03593668
Drug: Benaglutide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-week dose adjustment period（0-2weeks） \[before meals\] 0-2d: -; 0.1mg，iH; -; 3-4d: -; 0.1mg，iH; 0.1mg，iH; 5-6d: 0.1mg，iH; 0.1mg，iH; 0.1mg，iH; 7-9d: 0.1mg，iH; 0.2mg，iH; 0.1mg，iH; 10-11d: 0.1mg，iH; 0.2mg，iH; 0.2mg，iH; 12-14d: 0.2mg，iH; 0.2mg，iH; 0.2mg，iH.~10-week dose stabilization period（3-12weeks） Benaglutide Injection 0.2mg，100ul，tid，iH
Trial: NCT03364335
Drug: Leu Met Sil 1.0mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leu 1100 mg + Met 500mg + 1mg Sil BID
Trial: NCT00746603
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients will start at 10mg of simvastatin, and then, based on results of interim evaluation escalated to 20mg and then 40. Patients will stay on maximally tolerated dose of drug until the end of the study at 26 weeks.
Trial: NCT03364335
Drug: Leu Met Sil 4.0mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leu 1100 mg + Met 500mg + 4mg Sil BID
Trial: NCT03364335
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00728312
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 week comparison of placebo 5-15 mg per day (pill which contains no active medication) versus active medication (aripiprazole 5-15 mg per day)
Trial: NCT03591744
Drug: Pegylated Liposomal Doxorubicin Hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01510847
Drug: Andriol Testocaps
RxNorm normalized name: Pri-Andriol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, 40mg, Twice a day, 30days
Trial: NCT02324491
Drug: ZGN-440 for Injectable Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 52 weeks.
Trial: NCT02324491
Drug: ZGN-440 Placebo for Injectable Suspension
RxNorm normalized name: placebo 440 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive placebo twice weekly subcutaneous injections for up to 52 weeks.
Trial: NCT01665235
Drug: ACEI / ARB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
Trial: NCT00326378
Drug: CCRT arm without consolidation chemotherapy
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: definitive CCRT with weekly Docetaxel/CDDP #6 without consolidation chemotherapy
Trial: NCT02807064
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0,5 ml per os all days for 2 months
Trial: NCT00479024
Drug: iodinated contrast agent
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iodinated contrast agent either 370 stength of iopamidol or 320 strength of visipaque
Trial: NCT00562783
Drug: Vitaliver
RxNorm normalized name: Vital-Chlor
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00562783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00948818
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
Trial: NCT00130806
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02320695
Drug: Antibiotic/Pain Relieving Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03710941
Drug: REGN2477+REGN1033
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, sequential, repeat-dose Intravenous (IV) or matching placebo
Trial: NCT03710941
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single, sequential, repeat-dose Intravenous (IV)
Trial: NCT00663728
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT02529241
Drug: Group 2:LCB01-0371
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Period:LCB01-0371 Tablet 800 mg~2. Period: LCB01-0371 Tablet 1200 mg
Trial: NCT00488579
Drug: Two policies of iron prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60mg ferrous sulphate daily (+folic acid); Screening and therapy: Hb measurement on each visit, Hb\>9g/dl only folic acid, Hb\<9g/dl 60-120 of ferrous sulphate daily (+folic acid).
Trial: NCT02330549
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-matching CVC administered orally once daily and taken every morning with food.
Trial: NCT02696915
Drug: Intrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal hyperbaric bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms
Trial: NCT01490749
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation for Phase I; dose for Phase II to be determined after Phase I is completed.
Trial: NCT01490749
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive two cycles of XELOX.